KEGG   DRUG: Zenocutuzumab
Entry
D11991                      Drug                                   
Name
Zenocutuzumab (USAN/INN);
Zenocutuzumab-zbco;
Bizengri (TN)
Product
Formula
C6479H9971N1725O2027S45
Exact mass
145812.7612
Mol weight
145902.84
Sequence
(Heavy chain A)
QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYYMHWVRQA PGQGLEWMGW INPNSGGTNY
AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARDH GSRHFWSYWG FDYWGQGTLV
TVSSASTKGP SVFPLAPSSK STSGGTAALG CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV
LQSSGLYSLS SVVTVPSSSL GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE
LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTKPP
SREEMTKNQV SLKCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSKLTVD
KSRWQQGNVF SCSVMHEALH NHYTQKSLS SPG
(Heavy chain B)
QVQLVQSGAE VKKPGASVKL SCKASGYTFT AYYINWVRQA PGQGLEWIGR IYPGSGYTSY
AQKFQGRATL TADESTSTAY MELSSLRSED TAVYFCARPP VYYDSAWFAY WGQGTLVTVS
SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTDPPSRE
EMTKNQVSLT CEVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR
WQQGNVFSCS VMHEALHNHY TQKSLSLSPG
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCRASQSIS SYLNWYQQKP GKAPKLLIYA ASSLQSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYSTPPTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: A22-A96, A151-A207, A227-B214, A233-B230, A236-B233, A268-A328, A374-A432, B22-B96, B148-B204, B224-L'214, B265-B325, B371-B429, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Remark
Product: D11991<US>
Efficacy
Antineoplastic
  Disease
Non-small cell lung cancer (NRG1 fusion positive) [DS:H00014]
Pancreatic adenocarcinoma (NRG1 fusion positive) [DS:H00019]
  Type
Bispecific antibody
Target
ERBB2 (HER2, CD340) [HSA:2064] [KO:K05083]
ERBB3 (HER3) [HSA:2065] [KO:K05084]
  Pathway
hsa04012  ErbB signaling pathway
hsa04151  PI3K-Akt signaling pathway
hsa05212  Pancreatic cancer
hsa05223  Non-small cell lung cancer
  Network
nt06262  Pancreatic cancer
nt06266  Non-small cell lung cancer
nt06543  NRG-ERBB signaling
Brite
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    ERBB2 (HER2, CD340)
     D11991  Zenocutuzumab (USAN/INN) <US>
    ERBB3 (HER3)
     D11991  Zenocutuzumab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11991
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11991
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D11991
Other DBs
CAS: 1969309-56-5
PubChem: 497620404
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system